Role of Ertugliflozin in the Management of Diabetes Mellitus

The novel oral sodium-glucose cotransporter-2 (SGLT2) inhibitor Ertugliflozin (SteglatroTM) is introduced as a monotherapy or in conjunction with another antidiabetic drug regimen for the treatment of type 2 diabetes mellitus (T2DM).Additional safe and efficient treatment options for patients and ph...

Descripción completa

Detalles Bibliográficos
Autores principales: Totade, Manisha, Gaidhane, Shilpa A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2022
Materias:
Family/General Practice
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9744393/
https://www.ncbi.nlm.nih.gov/pubmed/36523727
http://dx.doi.org/10.7759/cureus.31404

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9744393/
https://www.ncbi.nlm.nih.gov/pubmed/36523727
http://dx.doi.org/10.7759/cureus.31404

Ejemplares similares